Baseline characteristics and endpoints of the GENDER and PROSPER studies.

<p>Data are presented as mean ± SD or number (%).</p>a<p>Cholesterol levels available in only 177 patients.</p>b<p>Before inclusion or during follow-up period.</p>c<p>During follow-up period.</p>d<p>During follow up of 10 years after inclusion in GENDER.</p

Hazard ratios and 95% CIs for the treatment effect of pravastatin relative to placebo by subgroups.

<p>Table provides number of subjects, number (percentage) of events, p-value within each subgroup and p for interaction (PI) across subgroups. Models adjusted for age, sex, current smoker, histories of diabetes, hypertension, coronary disease, cerebrovascular disease and peripheral vascular disease, BMI, SBP, DBP, HDL& LDL as appropriate.</p

Results of the gene set analysis of the non-homologous end joining pathway with myocardial infarction in GENDER and PROSPER.

<p>SNPs, total number of SNPs per gene; Sig.SNPs indicate the number of SNPs that passed the test constrains (P<0.2 and R2<0.5) and were thus jointly analyzed in 10,000 permutations; OR odds ratio; P, p-value; MAF, minor allele frequency.</p

Cumulative incidence plots for the combined endpoints of death or hospitalization for myocardial infarction (MI) or stroke (2a), death or hospitalization for stroke (2b), coronary deaths or hospitalizations for MI (2c) and coronary death or admission (2d) for the Scottish cohort.

<p>Numbers at risk are presented for each treatment group.</p

Set-based analysis of DNA repair pathways in the GENDER and PROSPER study populations.

<p>The SNPs per endpoint indicate the number of independent SNPs that passed the test constrains (P<0.2 and R²<0.5) and were thus jointly analyzed in 10,000 permutations.</p>a<p>Before inclusion or during follow-up period. MI, myocardial infarction.</p>b<p>Cases/controls.</p

Mortality outcomes in the full cohort: participants and deaths by randomized treatment group, hazard ratios (95% CIs) and p-values within the trial, in the post-trial period and overall.

<p>Mortality outcomes in the full cohort: participants and deaths by randomized treatment group, hazard ratios (95% CIs) and p-values within the trial, in the post-trial period and overall.</p

Cancer mortality and incident cancer outcomes in the full cohort: participants and participants with events by randomized treatment group, hazard ratios (95% CIs) and p-values within the trial, in the post-trial period and overall.

<p>Incident cancer results are repeated including minor skin cancers* and neoplasms of uncertain or unknown behaviour**.</p

Baseline characteristics by incident primary combined nonfatal and fatal endpoint (<i>p</i>-value versus no event group).

<p>Please note that because of the design structure of the trial—recruiting more participants with hypertension/smokers and diabetes (and women) into the low risk primary prevention group—the significance or nonsignificance of univariate comparisons in this table could be potentially misleading. <i>p</i>-Values for continuous variables are from two-sample <i>t</i>-test and for categorical variables from chi-squared test.</p>a<p>Values are geometric means (SD) calculated from the log-transformed distribution and the (<i>p</i>-value).</p><p>SD, standard deviation; TIA, transient ischemic attack.</p

Plot showing associations of 1-unit increase in log IL-6, log CRP, and fibrinogen with HR of endpoints on a log scale (after adjusting for randomized treatment, age, gender, LDL cholesterol, HDL cholesterol, triglycerides, BMI, systolic and diastolic blood pressure, current and exsmoking, diabetes, previous CVD, use of antihypertensive therapy, and country).

<p>Plot showing associations of 1-unit increase in log IL-6, log CRP, and fibrinogen with HR of endpoints on a log scale (after adjusting for randomized treatment, age, gender, LDL cholesterol, HDL cholesterol, triglycerides, BMI, systolic and diastolic blood pressure, current and exsmoking, diabetes, previous CVD, use of antihypertensive therapy, and country).</p

Associations of IL-6, CRP, and fibrinogen with risk (HR for 1-unit increase in log IL-6, log CRP, or fibrinogen) of experiencing one of the four categories of events.

<p>Event groupings as defined in the methods. Fatal CVD deaths preceded by nonfatal CVD are excluded. Model A, adjusted for randomized treatment. Model B, adjusted for randomized treatment, age, gender, LDL cholesterol, HDL cholesterol, systolic blood pressure, current smoker, diabetes, previous CVD (CHD, stroke, peripheral arterial disease, stroke, and transient ischaemic attack), use of antihypertensive therapy, and country. Model C, Model B+ adjusted for log triglyceride, BMI, diastolic blood pressure, exsmoker (as well as current smoker).</p